Rac1 is a novel therapeutic target in mantle cell lymphoma

[1]  S. Rule,et al.  Novel agents in mantle cell lymphoma , 2017, Expert review of anticancer therapy.

[2]  W. Chan,et al.  Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas , 2017, Haematologica.

[3]  S. Batra,et al.  RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment , 2016, Oncogene.

[4]  L. Staudt,et al.  The miRNA-17∼92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation , 2012, Leukemia.

[5]  David A. Williams,et al.  Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia. , 2011, Blood.

[6]  P. Mazur,et al.  Early requirement of Rac1 in a mouse model of pancreatic cancer. , 2011, Gastroenterology.

[7]  A. Wiestner,et al.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. , 2011, Blood.

[8]  Jennifer B Dennison,et al.  8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma. , 2010, Blood.

[9]  E. Hoster,et al.  Improvement of overall survival in advanced stage mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Bosco,et al.  Rac1 GTPase: A “Rac” of All Trades , 2009, Cellular and Molecular Life Sciences.

[11]  E. Campo,et al.  Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics , 2007, Nature Reviews Cancer.

[12]  Yi Zheng,et al.  Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[13]  David A. Williams,et al.  Critical Roles for Rac1 and Rac2 GTPases in B Cell Development and Signaling , 2003, Science.

[14]  L. Staudt,et al.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. , 2003, Cancer cell.

[15]  J. Gutkind,et al.  Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-κB , 2002, Oncogene.